Published in Hepatitis Weekly, August 23rd, 1999
Treatment with interferon alpha (IFN-(alpha)) has been shown to result in sustained loss of hepatitis B virus (HBV) DNA and hepatitis B e antigen (HBeAg) in between 25 percent to 40 percent of HBV positive patients.
More than half of HBV patients treated with IFN-(alpha), however, either do not achieve a response or relapse after initially responding. It is unclear whether these patients benefit from another cycle of IFN-(alpha).
"Attempts in pilot studies of retreatment with IFN-(alpha) for previous...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.